What's Stopping GLP-1s From Getting Cheaper
By CNBC
Community Score: 50% | 44.9K views | 2mo
0 community ratings: null thumbs up, null thumbs down
The push to make weight loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and rising regulatory scrutiny. The dispute centers on pharmaceutical compounding, which is legal for individualized patient needs, and whether it crossed into large-scale marketing. With semaglutide no longer in shortage, Novo says compounded versions are not justified. CNBC's Brandon Gomez reports. Produced and shot by: Charlotte Morabito Edited by: Andrea Miller Reporting by: Brandon Gomez, Annika Kim Constantino Senior Director of Video: Lindsey Jacobson Additional Footage: Getty Images » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Watch CNBC on the go with CNBC+: https://www.cnbc.com/WatchCNBCPlus About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favo
Tags: GLP-1 drugs, weight loss drugs regulation, compounded GLP-1s, semaglutide compounding, FDA GLP-1 marketing, GLP-1 lawsuits, weight loss drug pricing, GLP-1 shortages, Novo Nordisk patents, telehealth weight loss drugs
More from CNBC
- How The U.S. Became So Dependent On SpaceX — Score: 50%
- Millions Have Signed Up For Trump Accounts. But There Are Still A Lot Of Unanswered Questions — Score: 50%
- Supreme Court Says Trump’s Tariffs Are Illegal. Here’s What Happens Next — Score: 50%
- Why New Balance sales are soaring while Nike falls — Score: 50%
- How tariffs are pushing America’s furniture industry to the brink — Score: 50%
- United Airlines Overhauls MileagePlus Program — Here's What To Know — Score: 50%